More Stories

Informist, Friday, Nov. 28, 2025

MUMBAI – The Nifty Pharma index will continue to rise next week, carrying forward the momentum gained this week, according to analysts. Pharmaceutical stocks are likely to rally in the week ending Dec. 5 on the back of better-than-expected September quarter earnings performance and a positive outlook on pharmaceutical exports by market participants. 

India's pharmaceutical industry continues to strengthen globally despite the imposition of US tariffs, with the Pharmaceuticals Export Promotion Council of India (Pharmexcil) now featuring among the top five export promotion councils of the world with exports reaching $30.46 billion, according to media reports. 

The positive sentiment will also be boosted by reports of some developments on the trade front, according to a research analyst at a domestic brokerage. India and the US are likely to agree on the framework for a trade deal within this calendar year to address the reciprocal tariffs imposed by Washington on exports from New Delhi, Commerce Secretary Rajesh Agrawal said Friday. "We are very optimistic and very hopeful that we should find a solution within this calendar year," he said at the 98th FICCI annual general meeting Friday.

The Nifty Pharma is likely to move in the range of 22665 and 23100, according to Ganesh Angaj, research analyst at NVS Brokerage. For the week ended Friday, the index rose nearly 2% at 22998.30 points. Glenmark Pharmaceuticals was the biggest gainer, rising nearly 6% during the week.

TOP HEADLINES

* MedPlus Health Services arm's drug store gets 2-day licence suspension
* IPO Alert: Sudeep Pharma to list Fri, issue price set at INR 593 per share
* GST dept searches Emcure Pharma's offices Mon-Wed, co says no impact on ops
* Zydus Life gets US FDA tentative nod for Empagliflozin, Linagliptin tablets
* Neuland Lab board OKs INR 1.89 bln capex for relocating Hyderabad R&D center
* US FDA tags Glenmark Pharma's Monroe unit as 'voluntary action indicated'
* US FDA tags Biocon arm's Bengaluru facility as 'voluntary action indicated'
* Zydus Life, RK Pharma sign exclusive pact for novel sterile injectable
* ANALYSIS: Q2 PAT growth of pharma, healthcare cos best in 5 quarters
* US FDA approves updated label for Sun Pharma's UNLOXCYT skin cancer drug
* IPO Alert: Sudeep Pharma issue subscribed 94 times, QIBs bid 213 times
* Zydus Life gets US FDA final approval for verapamil hydrochloride tablets
* Trial in Sun Pharma plea over Artura Pharma's similar pdt names to go on: HC
* IPO Alert: Sudeep Pharma issue subscribed over 5 times as of second day
* Eris Life to acquire 30% stake in arm Swiss Parenterals for INR 4.23 bln
* Dr Reddy's, arms get European Commission's approval for AVT03
* Armenia health min issues no observation to Alkem Labs' Sikkim mfg unit
* US FDA issues 7 observations to Lupin's manufacturing facility in Goa
* IPO Alert: Sudeep Pharma issue subscribed 1.42 times on opening day
* US FDA issues 7 observations to Natco Pharma API mfg unit in Chennai

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

End

US$1 = INR 89.46

Reported by P. Madhu Kumar

Edited by Tanima Banerjee

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.